Patents by Inventor William Kaelin

William Kaelin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treatment using NBS-1, antibodies and proteins thereto, and uses of the antibodies
    Patent number: 7666997
    Abstract: Antibodies that will specifically bind to NBS-1 are described. It is also shown that NBS-1 will interact with p53 responsive elements in a p53 promoter. Thus, NBS-1 can be used in subjects having a p53-dependent tumor to inhibit growth of that tumor.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: February 23, 2010
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: William Kaelin, Christine Jost
  • Treatment of von hippel lindau disease
    Publication number: 20060252763
    Abstract: The present invention relates to a method of treating VHL comprising administering a therapeutically effective amount of a compound described in the specification to a warm-blooded animal in need thereof.
    Type: Application
    Filed: December 16, 2003
    Publication date: November 9, 2006
    Inventor: William Kaelin
  • In vivo imaging of e2f-fegulated bioluminescent proteins
    Publication number: 20060206950
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the identification of prolifering cells. Specifically, the present invention provides transgenic mice having a nucleic acid comprising an E2F responsive promoter operably linked to a nucleic acid encoding a bioluminescent protein. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and are potential treatments for various disease states and disease conditions such as cancer.
    Type: Application
    Filed: November 4, 2003
    Publication date: September 14, 2006
    Inventor: William Kaelin
  • Pharmaceuticals and methods for treating hypoxia and screening methods therefor
    Publication number: 20050186650
    Abstract: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.
    Type: Application
    Filed: December 30, 2004
    Publication date: August 25, 2005
    Inventors: William Kaelin, Mircea Ivan
  • Methods of treatment using NBS-1, antibodies and proteins thereto, and uses of the antibodies
    Publication number: 20020147173
    Abstract: Antibodies that will specifically bind to NBS-1 are described. It is also shown that NBS-1 will interact with p53 responsive elements in a p53 promoter. Thus, NBS-1 can be used in subjects having a p53-dependent tumor to inhibit growth of that tumor.
    Type: Application
    Filed: May 24, 2002
    Publication date: October 10, 2002
    Inventors: William Kaelin, Christine Jost
  • Methods of treatment using NBS-1, antibodies and proteins thereto, and uses of the antibodies
    Patent number: 6451979
    Abstract: Antibodies that will specifically bind to NBS-1 are described. It is also shown that NBS-1 will interact with p53 responsive elements in a p53 promoter. Thus, NBS-1 can be used in subjects having a p53-dependent tumor to inhibit growth of that tumor.
    Type: Grant
    Filed: May 12, 1998
    Date of Patent: September 17, 2002
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: William Kaelin, Christine Jost